Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
News|Articles|December 2, 2016
PTSM: Pharmaceutical Technology Sourcing and Management
- PTSM: Pharmaceutical Technology Sourcing and Management-12-07-2016
- Volume 11
- Issue 12
Recipharm Collaborates with Laccure AB
Author(s)Pharmaceutical Technology Editors
Recipharm and Laccure AB signed a commercial collaboration for the manufacture and delivery of Laccure’s bacterial vaginosis treatment.
Advertisement
On Dec. 1, 2016 Recipharm announced that it has entered a commercial collaboration with Laccure AB for the manufacture and delivery of Laccure Pessary, a non-prescription vaginal tablet for the treatment of bacterial vaginosis. Laccure Pessary will be manufactured, packaged, and distributed globally from Recipharm’s facility in Karlskoga that specializes in the production of semi-solid products. Recipharm and Laccure AB have now signed an agreement for commercial production of Laccure Pessary, and the exact date for the launch will be announced in 2017. Laccure Pessary is based on a patented substance that releases lactic acid.
Source:
Articles in this issue
almost 10 years ago
Factors to Consider in Dissolution Testingalmost 10 years ago
Internal and External Factors to Shape CMO Industryalmost 10 years ago
New Opportunities for Cocrystalsalmost 10 years ago
Analytical Method Validation Using QbD and QRMalmost 10 years ago
Vetter Processing Center Receives Data Certificationalmost 10 years ago
Idifarma Invests in Automatic Capsule Filling Capabilitiesalmost 10 years ago
Catalent Expands Softgel Capacity with Accucaps Acquisitionalmost 10 years ago
Patheon Acquires Roche API Sitealmost 10 years ago
FDA Guidance Helps Further Clarify Quality Agreementsalmost 10 years ago
PCI Expands Cryogenic Storage Facilities to Rockford SiteAdvertisement
Related to this article
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Jason Bertola, executive director of Commercial Development for the Advanced Synthesis Platform at Lonza in North America, explains the demand for spray drying and the hurdles involved with scale up, in an interview with PharmTech.
The company is showcasing new development solutions and advanced digital technologies including its new OSD Express and Steriles Express solutions for drug development.
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
2
Manufacturing Intelligence: Organoids, Organ-on-a-Chip, and the Trust Gap
3
Complying with International Pharmacopoeias
4
CPHI Milan: Packaging and Delivery Decisions Must Reflect Real-World Care
5